JP2020520357A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520357A5
JP2020520357A5 JP2019563492A JP2019563492A JP2020520357A5 JP 2020520357 A5 JP2020520357 A5 JP 2020520357A5 JP 2019563492 A JP2019563492 A JP 2019563492A JP 2019563492 A JP2019563492 A JP 2019563492A JP 2020520357 A5 JP2020520357 A5 JP 2020520357A5
Authority
JP
Japan
Prior art keywords
pyrimidine
thiophene
ethylamino
benzo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563492A
Other languages
English (en)
Japanese (ja)
Other versions
JP7093791B2 (ja
JP2020520357A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/062843 external-priority patent/WO2018210987A1/en
Publication of JP2020520357A publication Critical patent/JP2020520357A/ja
Publication of JP2020520357A5 publication Critical patent/JP2020520357A5/ja
Application granted granted Critical
Publication of JP7093791B2 publication Critical patent/JP7093791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563492A 2017-05-18 2018-05-17 Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 Active JP7093791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017061987 2017-05-18
EPPCT/EP2017/061987 2017-05-18
PCT/EP2018/062843 WO2018210987A1 (en) 2017-05-18 2018-05-17 Benzofurane and benzothiophene derivatives as pge2 receptor modulators

Publications (3)

Publication Number Publication Date
JP2020520357A JP2020520357A (ja) 2020-07-09
JP2020520357A5 true JP2020520357A5 (enExample) 2021-07-26
JP7093791B2 JP7093791B2 (ja) 2022-06-30

Family

ID=62196583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563492A Active JP7093791B2 (ja) 2017-05-18 2018-05-17 Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体

Country Status (10)

Country Link
US (1) US11325899B2 (enExample)
EP (1) EP3625227B1 (enExample)
JP (1) JP7093791B2 (enExample)
KR (1) KR102612649B1 (enExample)
CN (1) CN110621671A (enExample)
AR (1) AR111807A1 (enExample)
CA (1) CA3063632A1 (enExample)
ES (1) ES2929309T3 (enExample)
TW (1) TW201900179A (enExample)
WO (1) WO2018210987A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3601233B1 (en) 2017-03-27 2024-08-14 Hydro-Québec Salts for use in electrolyte compositions or as electrode additives
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Agc株式会社 プロスタグランジンe2レセプターep2/ep4デュアルアンタゴニスト
US20220048987A1 (en) * 2020-08-13 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Method of treatment to prevent or reverse age-associated inflammation, cognitive decline, and neurodegeneration
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
JP2024524981A (ja) 2021-06-24 2024-07-09 レザボア ニューロサイエンス,インコーポレイテッド Ep2アンタゴニスト化合物
CN114539193B (zh) * 2022-01-20 2024-08-06 安徽普利药业有限公司 一种盐酸胺碘酮中间体的制备方法
WO2024102968A1 (en) * 2022-11-10 2024-05-16 Tempest Therapeutics, Inc. Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
ATE395058T1 (de) 2000-03-24 2008-05-15 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
AU2003233297A1 (en) 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
DE602004013938D1 (de) 2003-01-29 2008-07-03 Asterand Uk Ltd Hemmstoffe des ep4-rezeptors
CA2536887C (en) 2003-08-26 2012-03-06 Teijin Pharma Limited Pyrrolopyrimidinone derivatives
WO2005021508A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
BRPI0510598A (pt) 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AU2006246930C1 (en) 2005-05-19 2012-01-19 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP2013169B1 (en) 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
ES2393932T3 (es) 2006-07-14 2013-01-02 Novartis Ag Derivados de Pirimidina como inhibidores de ALK-5
CN101541778B (zh) 2006-08-11 2014-10-08 默克加拿大有限公司 作为ep4受体配体的噻吩甲酰胺衍生物
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US8158671B2 (en) 2007-02-26 2012-04-17 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
CA2681861A1 (en) 2007-03-26 2008-10-16 Astellas Pharma Inc. Ornithine derivative
JP2010522218A (ja) 2007-03-26 2010-07-01 メルク フロスト カナダ リミテツド Ep4受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
US9029414B2 (en) 2008-09-19 2015-05-12 Biotechnology Research Corporation Triterpenoid compounds and methods of use thereof
CN102224154A (zh) 2008-09-25 2011-10-19 默克弗罗斯特加拿大有限公司 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
US20110124667A1 (en) 2009-11-23 2011-05-26 Philip Manton Brown Methods for the treatment of irritable bowel syndrome
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
HRP20170042T1 (hr) 2010-09-21 2017-03-10 Eisai R&D Management Co., Ltd. Farmaceutski pripravak
CN106046158A (zh) 2010-09-29 2016-10-26 株式会社Nb健康研究所 针对人前列腺素e2 受体ep4 的抗体
WO2012066070A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
BR112013024378A2 (pt) 2011-03-24 2016-12-13 Chemilia Ab novos derivados de pirimidina
WO2012149528A1 (en) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
US9518044B2 (en) 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
CN103702980B (zh) 2011-07-04 2016-10-05 罗达制药生物技术有限责任公司 环胺衍生物作为ep4受体拮抗剂
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
BR112015011497B1 (pt) 2012-11-27 2023-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Composto, e, formulação farmacêutica
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
SG11201510121RA (en) 2013-06-12 2016-01-28 Kaken Pharma Co Ltd 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2675027T3 (es) 2013-09-06 2018-07-05 Aurigene Discovery Technologies Limited Derivados de 1,2,4-oxadiazol como inmunomoduladores
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
JP6374959B2 (ja) 2013-10-17 2018-08-15 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna−pk阻害剤
SI3057953T1 (sl) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
DK3083554T3 (da) 2013-12-17 2019-05-13 Lilly Co Eli Dimethylbenzoesyreforbindelser
RS56615B1 (sr) 2013-12-17 2018-02-28 Lilly Co Eli Derivati fenoksietil cikličnih amina i njihova aktivnost kao modulatora ep4 receptora
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ep4配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
WO2015167825A1 (en) 2014-04-29 2015-11-05 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
CN110354266A (zh) 2014-05-23 2019-10-22 卫材 R&D 管理有限公司 用于治疗癌症的组合疗法
JP6635949B2 (ja) 2014-06-04 2020-01-29 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのmth1阻害剤
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
TWI739666B (zh) 2015-01-09 2021-09-11 日商小野藥品工業股份有限公司 醫藥組成物
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
KR102684436B1 (ko) 2015-10-16 2024-07-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Ep4 길항제
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP4219462A1 (en) 2016-07-13 2023-08-02 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
JP7065117B2 (ja) 2017-05-18 2022-05-11 イドーシア ファーマシューティカルズ リミテッド N-置換インドール誘導体
PE20191811A1 (es) 2017-05-18 2019-12-26 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives

Similar Documents

Publication Publication Date Title
JP2020520357A5 (enExample)
JP2020520354A5 (enExample)
JP2020520358A5 (enExample)
JP2020520356A5 (enExample)
JP2018534328A5 (enExample)
IL259424A (en) History of indole converted to nitrogen as pge2 receptor modulators
RU2573834C2 (ru) ФАРМАЦЕВТИЧЕСКИ АКТИВНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
AU2017258834B2 (en) Multisubstituted aromatic compounds as serine protease inhibitors
JP6464139B2 (ja) ブロモドメイン含有タンパク質の阻害のための方法および組成物
ES2274047T3 (es) Derivados de vinilfenilo como activadores de glk.
JP2017537948A5 (enExample)
JP4860606B2 (ja) 糖尿病の処置にglkアクチベーターとして用いるためのヘテロアリールベンズアミド誘導体
HRP20180413T1 (hr) Inhibitori kinaza koji reguliraju signalne puteve u apoptozi
KR101675984B1 (ko) 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
JP2007519694A5 (enExample)
CA2554686A1 (en) Compounds
JP2018535999A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2007523182A5 (enExample)
JP2017522346A5 (enExample)
JP2009524589A5 (ja) 置換されたイソキノリン−1,3(2h,4h)−ジオン、1−チオキソ−1,4−ジヒドロ−2h−イソキノリン−3−オン、および1,4−ジヒドロ−3(2h)−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用
EP1578745A1 (en) Benzofuran derivates, process for their preparation and intermediates thereof
JP2008513514A5 (enExample)
JP2009536196A5 (enExample)
JP2010533158A5 (enExample)